On the occasion of **1 year CAR-T in Belgium** we have the pleasure to invite you to this symposium on CAR-T therapy

Wednesday – 14 / 10 / 2020

→ **A LINK FOR ATTENDING THIS VIRTUAL MEETING WILL BE SEND AFTER REGISTRATION**

Scientific program : 19h-22h

- Introduction (10min)

- Patient identification and referral in the real world, need for a consensus statement
  Prof. Peter Vandenberghe & Prof.Tessa Kerre (30min)

- First Belgian real world evidence in DLBCL: A retrospective study
  Dr. Sarah Bailly and Dr. Sophie Servais (30min)

- CAR-T treatment for patients with pALL: A large Belgian experience
  Prof. Barbara De Moerloose (30min)

- CART treatment for patients with DLBCL: The US real world evidence
  Prof. David Porter (30min)

- Panel discussion: From treating physician to CAR-T center and back
  Discussion with selected members of the faculty and representatives of large non-academic centers
  moderated by Dr. Vanessa Van Hende (50min)

Faculties :

This symposium is the result of a collaboration between physicians of 4 academic hematology departments and an Academic Pediatric hematology/Oncology department with the support of Novartis.

UZ LEUVEN | UZ GENT | SAINT-LUC UCL BRUXELLES | CHU de Liège

- **Prof. Peter Vandenberghe** - (UZ Leuven)

- **Prof. Barbara De Moerloose | Prof. Tessa Kerre | Prof. Fritz Offner** - (UZ Gent)

- **Prof. Eric Van Den Neste | Dr. Sarah Bailly** - (Cliniques Universitaires Saint-Luc)

- **Prof. Yves Beguin | Dr. Sophie Servais** - (CHU Liège)

Guest Lecture

• **Prof. David Porter**

Prof. Porter is an oncologist in Philadelphia, Pennsylvania, with a subspecialty in hematologic oncology and more than 20 years of practice. He's affiliated with UPMC presbyterian Shadyside and University of Pennsylvania-Penn Presbyterian.

Moderator panel discussion

• **Dr. Vanessa Van Hende** - (Hematology AZ Nikolaas)

Please register in advance on my.novartis.be/symposium-1-year-cart
Or confirm your presence to your Novartis representative before **28th of September 2020**